PALO ALTO, Calif., Sept. 12, 2019 /PRNewswire/ -- Kodiak Sciences
Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company
specializing in novel therapeutics to treat chronic,
high-prevalence retinal diseases, today announced that updated data
from the clinical development program for its investigational
therapy KSI-301 will be presented at The Retina Society Annual
Meeting on September 15 in
London, U.K.
"Developing intravitreal medicines with meaningfully
differentiated durability has been Kodiak's objective since our
founding one decade ago. Kodiak's announcement at this weekend's
Retina Society Annual Meeting takes us another step closer to
providing a transformative new therapeutic option to
patients. I believe KSI-301 has the potential to be a
first-line anti-VEGF agent for patients suffering from retinal
vascular diseases," said Victor
Perlroth, M.D., Chief Executive Officer of Kodiak Sciences.
"We are pleased to have Dr. David
Brown present the emerging durability data from our ongoing
Phase 1b study of KSI-301 with the
community on September 15. His
presentation represents a key early look into KSI-301's durability
in advance of a more detailed data presentation planned for the
American Academy of Ophthalmology Retina Subspecialty Day on
October 11."
Details of the presentation are as follows:
Oral Presentation: Novel Anti-VEGF Antibody Biopolymer
Conjugate KSI-301 with Potential for Extended Durability in Retinal
Vascular Diseases: Late-Breaking Results from a Phase 1b Study in Patients with wAMD, DME and RVO
Presenter: David M. Brown, M.D., FACS -- Clinical
Professor of Ophthalmology at Baylor College
of Medicine, and Vice-Chair for Research at the Blanton Eye
Institute, Houston Methodist Hospital; Partner at Retina
Consultants of Houston,
Houston, TX
Presentation date and time: Sunday, September 15,
2019 – 11:08am BST
The slide presentation will be available on the Kodiak Investor
Relations website at http://ir.kodiak.com/ at the time of the
presentation.
About KSI-301
KSI-301 is an investigational therapy built on the Company's ABC
Platform and is designed to maintain potent and effective drug
levels in ocular tissues for longer than existing agents. Kodiak's
objective with KSI-301 is to develop a new first-line agent to
improve outcomes for patients with retinal vascular diseases and to
enable earlier treatment and prevention of vision loss for patients
with diabetic eye disease. KSI-301 is being developed and is fully
owned globally by Kodiak Sciences Inc.
About Kodiak Sciences Inc.
Kodiak™ is a clinical-stage biopharmaceutical company
specializing in novel therapeutics to treat chronic,
high-prevalence retinal diseases. We are focused on bringing new
science to the design and manufacture of next generation retinal
medicines to prevent and treat the leading causes of blindness
globally. Our ABC Platform™ merges the fields of antibody-based and
chemistry-based therapies and is at the core of Kodiak's discovery
engine. Kodiak's lead product candidate, KSI-301, is a novel
anti-VEGF antibody biopolymer conjugate being developed for the
treatment of retinal vascular diseases including age-related
macular degeneration and diabetic eye diseases. Kodiak has
leveraged its ABC Platform to build a pipeline of product
candidates in various stages of development including KSI-501, our
bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of
neovascular retinal diseases with an inflammatory component. Kodiak
is based in Palo Alto, CA. For
more information, visit www.kodiak.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995. These forward-looking
statements are not based on historical fact and include statements
regarding our platform technology and potential therapies, future
development plans, clinical and regulatory objectives and the
timing thereof, anticipated design of planned clinical trials,
expectations regarding the potential efficacy and commercial
potential of our product candidates, including KSI-301, the
anticipated presentation of data, the results of our research and
development efforts and our ability to advance our product
candidates into later stages of development. Forward-looking
statements generally include statements that are predictive in
nature and depend upon or refer to future events or conditions, and
include words such as "may," "will," "should," "would," "expect,"
"plan," "believe," "intend," "pursue," and other similar
expressions among others. Any forward-looking statements are based
on management's current expectations of future events and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks
and uncertainties include, but are not limited to, the preliminary
safety, efficacy and durability data for our KSI-301 product
candidate from the Phase 1 study will not continue or persist;
cessation or delay of any of the ongoing clinical studies and/or
our development of KSI-301 may occur; future potential regulatory
milestones of KSI-301, including those related to current and
planned clinical studies may be insufficient to support regulatory
submissions or approval; anticipated presentation of data at
upcoming conferences may not occur; our research and development
efforts and our ability to advance our product candidates into
later stages of development may fail; any one or more of our
product candidates may not be successfully developed, approved or
commercialized; adverse conditions in the general domestic and
global economic markets; as well as the other risks identified in
our filings with the Securities and Exchange Commission. For a
discussion of other risks and uncertainties, and other important
factors, any of which could cause our actual results to differ from
those contained in the forward-looking statements, see the section
entitled "Risk Factors" in our most recent Form 10-Q, as well as
discussions of potential risks, uncertainties, and other important
factors in our subsequent filings with the Securities and Exchange
Commission. These forward-looking statements speak only as of the
date hereof and Kodiak undertakes no obligation to update
forward-looking statements, and readers are cautioned not to place
undue reliance on such forward-looking statements.
"Kodiak," "ABC Platform" and the Kodiak logo are registered
trademarks or trademarks of Kodiak Sciences Inc. in various
jurisdictions.
View original
content:http://www.prnewswire.com/news-releases/kodiak-sciences-to-release-durability-data-from-clinical-development-program-of-ksi-301-for-wet-amd-at-the-retina-society-annual-meeting-300916836.html
SOURCE Kodiak Sciences Inc.